The Role of Plasma Neurofilament Light Protein for Assessing Cognitive Impairment in Patients With End-Stage Renal Disease
Open Access
- 28 May 2021
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Aging Neuroscience
- Vol. 13
Abstract
Introduction:End-stage renal disease (ESRD) is defined as the irreversible loss of renal function, necessitating renal replacement therapy. Patients with ESRD tend to have more risk factors for cognitive impairment than the general population, including hypertension, accumulative uremic toxin, anemia, and old age. The association between these risk factors and the pathologic protein was lacking. Blood-based assays for detecting pathologic protein, such as amyloid beta (Aβ), total tau protein, and neurofilament light chain (NfL), have the advantages of being less invasive and more cost-effective for diagnosing patients with cognitive impairment. The aim of the study is to validate if the common neurologic biomarkers were different in ESRD patients and to differentiate if the specific biomarkers could correlate with specific correctable risk factors.Methods:In total, 67 participants aged >45 years were enrolled. The definition of ESRD was receiving maintenance hemodialysis for >3 months. Cognitive impairment was defined as a Mini-Mental State Examination score of Summary of results:The study enrolled 43 patients with ESRD who did not have cognitive impairment and 24 patients with ESRD who had cognitive impairment [Mini-Mental State Examination (MMSE): 27.60 ± 1.80 vs. 16.84 ± 6.40,p< 0.05]. Among the blood-based biomarkers, NfL was marginally higher in the ESRD with cognitive impairment group than in the ESRD without cognitive impairment group (10.41 ± 3.26 vs. 8.74 ± 2.81 pg/mL,p= 0.037). The concentrations of tau protein, amyloid β 1/42, and amyloid β 1/40 (p= 0.504, 0.393, and 0.952, respectively) were similar between the two groups. The area under the curve of NfL to distinguish cognitively impaired and unimpaired ESRD patients was 0.687 (95% confidence interval: 0.548–0.825,p= 0.034). There was no correlation between the concentration of NfL and MMSE among total population (r= −0.153,p= 0.277), patients with (r= 0.137,p= 0.583) or without cognitive impairment (r= 0.155,p= 0.333).Conclusion:Patients with ESRD who had cognitive impairment had marginally higher plasma NfL concentrations. NfL concentration was not correlated with the biochemical parameters, total MMSE among total population or individual groups with or without cognitive impairment. The concentrations of Aβ1/40, Aβ1/42, and tau were similar between the groups.Keywords
Funding Information
- Ministry of Science and Technology, Taiwan
This publication has 85 references indexed in Scilit:
- Visual attention deficits in Alzheimer's disease: Relationship to HMPAO SPECT cortical hypoperfusionNeuropsychologia, 2011
- The intricate mechanisms of neurodegeneration in prion diseasesTrends in Molecular Medicine, 2011
- The Effect of Donepezil Treatment on Cardiovascular MortalityClinical Pharmacology & Therapeutics, 2010
- Chronic Kidney Disease and End-Stage Renal Disease in the Elderly Population: Current Prevalence, Future Projections, and Clinical SignificanceAdvances in Chronic Kidney Disease, 2010
- The Relationship Between Education Level and Mini-Mental State Examination Domains Among Older Mexican AmericansJournal of Geriatric Psychiatry and Neurology, 2010
- Detecting Dementia With the Mini-Mental State Examination in Highly Educated IndividualsArchives of Neurology, 2008
- 3D Mapping of Mini-mental State Examination Performance in Clinical and Preclinical Alzheimer DiseaseAlzheimer Disease & Associated Disorders, 2006
- Malnutrition–Inflammation–Atherosclerosis (MIA) Syndrome Components in Hemodialysis and Peritoneal Dialysis PatientsRenal Failure, 2006
- Localization of the brain calculation function area with MRIChinese Science Bulletin, 2001
- “Mini-mental state”Journal of Psychiatric Research, 1975